Skip to main content

Table 2 Adverse events

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

  ALL Patients (n = 30)
Total Grade3/4/5
All adverse events
 Any event 30 (100) 21 (70)
 Hepatotoxicity   
  high ALT 4 (13) 2 (7)
 Gastrointestinal Disorders
  nausea 21 (70) 1 (3)
  vomiting 14 (47) 0
  diarrhea 23 (77) 3 (10)
   C. difficile colitis 1 (3) 1 (3)
 Electrolyte
      hypophosphatemia 4 (13) 2 (7)
     hypokalemia 6 (20) 1 (3)
      hypomagnesemia 8 (27) 1 (3)
 Hematological
  anemia 4 (13) 2 (7)
  febrile neutropenia 2 (7) 2 (7)
  neutropenia 8 (27) 5 (17)
  thrombocytopenia 6 (20) 3 (10)
 Nervous System
  seizure 2 (7) 1 (3)
  vasovagal reaction 1 (3) 1 (3)
 Infection   
  pneumonia 1 (3) 1 (3)
 Constitutional
  fatigue 17 (57) 2 (7)
 Vascular Disorder
  pulmonary embolism 1 (3) 1 (3)
Immune-related adverse events   
 Any event 26 (87) 4 (13)
 Gastrointestinal Disorders
  diarrhea 11 (37) 2 (7)
  vomiting 6 (20) 0
  autoimmune colitis 1 (3) 1 (3)
 Endocrine
  hypothyroidism 1 (3) 0
  pituitary disorder 1 (3) 0
 Skin Disorders
  rash 7 (23) 0
  pruritus 9 (30) 0
  urticaria 1 (3) 0
  vitiligo 1 (3) 0
  erythroderma 1 (3) 0
 Constitutional
  fatigue 11 (37) 1 (3)